MA32438B1 - Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant - Google Patents

Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant

Info

Publication number
MA32438B1
MA32438B1 MA33084A MA33084A MA32438B1 MA 32438 B1 MA32438 B1 MA 32438B1 MA 33084 A MA33084 A MA 33084A MA 33084 A MA33084 A MA 33084A MA 32438 B1 MA32438 B1 MA 32438B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
compositions containing
antagonist activity
releasing factor
corticotropin releasing
Prior art date
Application number
MA33084A
Other languages
Arabic (ar)
English (en)
Inventor
Katsumi Kobayashi
Kazuyoshi Aso
Takafumi Takai
Takuto Kojima
Kazuyuki Tokumaru
Michiyo Mochizuki
Yasutaka Hoashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32438B1 publication Critical patent/MA32438B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un composé représenté par la formule (i') dans laquelle x est de l'azote ou crx, rx est de l'hydrogène, etc., r1 est un groupe hydrocarbure éventuellement substitué, etc., r2 est un groupe hydrocarbure éventuellement substitué, etc., le noyau a est un noyau hétérocyclique de 5 à 8 chaînons, etc., et y1, y2 et y3 sont chacun du carbone ou de l'azote éventuellement substitués, etc.. L'invention concerne également un sel ou un promédicament dudit composé, présentant une activité antagoniste sur le récepteur crf, ainsi que leur utilisation.
MA33084A 2008-01-22 2010-08-13 Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant MA32438B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US655408P 2008-01-22 2008-01-22
PCT/JP2009/051299 WO2009093747A1 (fr) 2008-01-22 2009-01-21 Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
MA32438B1 true MA32438B1 (fr) 2011-07-03

Family

ID=40637104

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33084A MA32438B1 (fr) 2008-01-22 2010-08-13 Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant

Country Status (26)

Country Link
US (2) US8785460B2 (fr)
EP (1) EP2240485B1 (fr)
JP (1) JP5431341B2 (fr)
KR (1) KR20100130596A (fr)
CN (1) CN101981031A (fr)
AR (1) AR070218A1 (fr)
AU (1) AU2009206936A1 (fr)
BR (1) BRPI0907230A2 (fr)
CA (1) CA2712347A1 (fr)
CL (1) CL2009000116A1 (fr)
CO (1) CO6230982A2 (fr)
CR (1) CR11636A (fr)
DO (1) DOP2010000226A (fr)
EA (1) EA201070876A1 (fr)
EC (1) ECSP10010414A (fr)
GE (1) GEP20125637B (fr)
IL (1) IL207074A0 (fr)
MA (1) MA32438B1 (fr)
MX (1) MX2010008039A (fr)
NZ (1) NZ587215A (fr)
PE (1) PE20091439A1 (fr)
SG (1) SG189803A1 (fr)
TW (1) TW200936591A (fr)
UY (1) UY31604A1 (fr)
WO (1) WO2009093747A1 (fr)
ZA (1) ZA201005340B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
AU2010214101A1 (en) 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
JP2013504580A (ja) * 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法
ES2561105T3 (es) 2011-08-18 2016-02-24 Nippon Shinyaku Co., Ltd. Derivado heterocíclico como inhibidor de prostaglandina E sintasa microsómica (mPGES)
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
CN103435618B (zh) * 2013-08-22 2016-03-23 中国药科大学 一种合成稠杂环化合物的方法
BR112016024749A2 (pt) * 2014-05-23 2017-08-15 Active Biotech Ab composto, composição farmacêutica, e, método de tratamento de câncer, de um distúrbio inflamatório, de um distúrbio de autoimunidade ou de um distúrbio neurodegenerativo
CN105859630B (zh) * 2015-01-22 2019-01-18 北京大学 一种咪唑酮衍生物的合成方法及应用
US20180269407A1 (en) 2015-10-01 2018-09-20 Idemitsu Kosan Co., Ltd. Benzimidazolo[1,2-a]benzimidazole carrying triazine groups for organic light emitting diodes
EP3150604B1 (fr) 2015-10-01 2021-07-14 Idemitsu Kosan Co., Ltd. Groupes benzimidazolo [1,2-a] benzimidazoles portant des benzimidazolo [1,2-a] benzimidazolyles, groupes carbazolyles, groupes benzofuranes ou benzothiophènes pour diodes électroluminescentes organiques
WO2018220513A1 (fr) * 2017-05-31 2018-12-06 Alembic Pharmaceuticals Limited Procédé amélioré de préparation d'acide obéticholique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS516993A (en) 1974-07-05 1976-01-20 Dainippon Pharmaceutical Co Adeninjudotaino seiho
AU2002226674B2 (en) 2000-12-28 2007-03-22 Ono Pharmaceutical Co., Ltd. Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2004113300A1 (fr) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique tricyclique
JP4790703B2 (ja) 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
JP2010507664A (ja) 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
WO2008082003A1 (fr) 2006-12-29 2008-07-10 Takeda Pharmaceutical Company Limited Composes heterocycliques lies par fusion developpant une activite antagoniste au crf
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
JP2011510030A (ja) * 2008-01-22 2011-03-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミノ−ベンゾイミダゾール類、該化合物を含む医薬、これらの使用及びこれらの製造方法
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
JP5431341B2 (ja) 2014-03-05
US20090186879A1 (en) 2009-07-23
CR11636A (es) 2010-11-04
EP2240485A1 (fr) 2010-10-20
CO6230982A2 (es) 2010-12-20
WO2009093747A1 (fr) 2009-07-30
CA2712347A1 (fr) 2009-07-30
EA201070876A1 (ru) 2011-04-29
EP2240485B1 (fr) 2014-10-15
GEP20125637B (en) 2012-09-10
MX2010008039A (es) 2010-08-10
IL207074A0 (en) 2010-12-30
AU2009206936A1 (en) 2009-07-30
CL2009000116A1 (es) 2010-08-27
BRPI0907230A2 (pt) 2019-09-24
TW200936591A (en) 2009-09-01
US8785460B2 (en) 2014-07-22
SG189803A1 (en) 2013-05-31
DOP2010000226A (es) 2010-10-15
ECSP10010414A (es) 2010-09-30
UY31604A1 (es) 2009-08-31
KR20100130596A (ko) 2010-12-13
US8901141B2 (en) 2014-12-02
ZA201005340B (en) 2011-10-26
AR070218A1 (es) 2010-03-25
PE20091439A1 (es) 2009-10-19
JP2011509923A (ja) 2011-03-31
CN101981031A (zh) 2011-02-23
NZ587215A (en) 2012-08-31
US20100298287A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
Capela et al. Design and evaluation of primaquine-artemisinin hybrids as a multistage antimalarial strategy
MX2010008039A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos.
SI1716152T1 (sl) Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
PE20141202A1 (es) Compuesto de ciclopropanoamina
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
DE602005014086D1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
EA201070635A1 (ru) Соединения, ингибирующие дипептидилпептидазу-iv,способы их получения и фармацевтические композиции, содержащие их в качестве активного агента
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
PH12013500442A1 (en) Fused bicyclic compound
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
WO2009057784A1 (fr) Composé hétérocyclique
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
NO20080563L (no) Pyrazol[3,4-d]azepinderivater som histamin H3 antagonister
EP2238105A4 (fr) Nouveaux composés, isomère ou sels pharmaceutiquement acceptables de ces derniers, utilisés comme antagonistes du récepteur vanilloïde, et compositions pharmaceutiques les contenant
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
EA201001842A1 (ru) Новые соединения, обладающие активностью антагонистов мускариновых рецепторов
DE602006017111D1 (de) Chinazolinon-derivate als vanilloid-antagonisten
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
DE602007005387D1 (de) Ptors
WO2008098077A3 (fr) Composés thérapeutiques